Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AIMIX Ranks No.1, Lotriga Soars in GP Market: Rep Track Survey
January 25, 2013
- JSMI Chief Yoshino Voices Disagreement with JMA on Epadel OTCs
January 25, 2013
- Transparency GL: Drug Makers Might Disclose Individual Payments Only Upon Request
January 24, 2013
- Takeda Establishes Trading Company in China to Serve as Base for Import of Finished Products
January 24, 2013
- Bayer, Santen Aim to Lead Market with Simpler Eylea Administration
January 24, 2013
- Merck Serono Aims for Top 10 Slot in Oncology Field
January 23, 2013
- AZ Initiates First Multinational PI Study under Agreement with NCC
January 23, 2013
- DSP Establishes Subsidiary in Singapore Eyeing Development of Business Operations for Latuda in Asia
January 23, 2013
- Kobayashi Kako, Elmed Eisai Set to Launch Allegra Generics on February 1
January 23, 2013
- Sanofi’s Dellegra Promotion to Home in on Stuffy Nose
January 22, 2013
- Santen Obtains Approval for Preservative-Free Ophthalmic Solution Tapros
January 22, 2013
- Kyorin and Daiichi Sankyo to Cancel Agreement on Uritos in Brazil
January 22, 2013
- Pfizer Detailing Infectious Disease Portfolios across Divisions
January 21, 2013
- Tokyo District Court to Issue Ruling on Actos Patent Suit on Feb. 27 after Takeda Lost Legal Battle in Osaka
January 21, 2013
- Drug Makers’ Specialty Care Pipelines Hit Snags in Late-Stage Development
January 21, 2013
- Daiichi Sankyo to Integrate Business Operations in Thailand with Ranbaxy
January 21, 2013
- Japan Could Get Left Behind in New Age of Open Innovation: Dr Fujimoto of Eli Lilly Japan
January 21, 2013
- Maruho to License Infantile Hemangioma Treatment from French Company
January 18, 2013
- Teijin Pharma Launches Acromegaly Treatment Somatuline
January 18, 2013
- Celgene K.K. Focused on MR Training Aiming for No. 1 Ranking Among Hematologists in 2013
January 18, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…